Cognition Therapeutics (CGTX) News
Filter CGTX News Items
CGTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CGTX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CGTX News From Around the Web
Below are the latest news stories about COGNITION THERAPEUTICS INC that investors may wish to consider to help them evaluate CGTX as an investment opportunity.
Cognition Therapeutics CEO Participating in Longwood and Sachs ConferencesPURCHASE, N.Y., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that CEO Lisa Ricciardi will be participating at upcoming conferences taking place during the week of the JP Morgan Healthcare Conference 2025. “I am looking forward to these opportunities to discuss the incredible progress we have made in 2024 with our Alzheimer’s and dementia wi |
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies dataB. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The company’s topline results from the Phase 2 SHIMMER study of CT1812 in patients with dementia with Lewy bodies exceeded expectations in terms of consistency and magnitude of treatment effect, the analyst tells investors in a research note. The firm says Cognition is “here to stay, even thrive now” on the back of these results. Published first on TheFly – the ult |
Cognition Therapeutics announces results in Phase 2 study of CT1812Cognition Therapeutics (CGTX) announced topline results from the exploratory Phase 2 ‘SHIMMER’ study demonstrating CT1812 produced strong therapeutic responses across behavioral, functional, cognitive, and movement measures in patients with dementia with Lewy bodies. Designed as a signal-finding study, the SHIMMER Phase 2 study enrolled 130 patients with mild-to-moderate DLB who were randomized to receive one of two oral doses of CT1812 or placebo daily for six months. Results indicate the study |
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials - - Full Results to be Presented at International Lewy Body Dementia Conference (ILBDC) - - Cognition Therapeutics and Dr. Galvin, a Principal Investigator, Will Host a Conference Call at 8am ET on December 18 to Review the Topline Data - PURCHASE, N.Y., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company de |
We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn RateThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Cognition Therapeutics (CGTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowCognition Therapeutics (CGTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
Cognition Therapeutics provided an update on Phase 2 ‘SHINE’ study analysisCognition Therapeutics (CGTX) provided an update on a biomarker analysis from the Phase 2 ‘SHINE’ study in mild-to-moderate Alzheimer’s disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau2172. Several blood-based measures of Alzheimer’s disease biology were identified that were normalized in CT1812-treated participants compared to the placebo-treated participants. These biomarker changes occurred in concert with a 95% |
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). The Company anticipates that topline results will be a |
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population- Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology - - Findings Support Disease-modifying Potential of CT1812 - PURCHASE, N.Y., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, provided an update on a biomarker1 analysis from the Phase 2 ‘SHINE’ study in mild-to |
Life Sciences Investor Forum: Presentations Now Available for Online ViewingCompany Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held November 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4fMrinK The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download inve |